S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
New AI Stock Payouts (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
New AI Stock Payouts (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
New AI Stock Payouts (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
New AI Stock Payouts (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
New AI Stock Payouts (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
New AI Stock Payouts (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
New AI Stock Payouts (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
New AI Stock Payouts (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
New AI Stock Payouts (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
New AI Stock Payouts (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
New AI Stock Payouts (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
New AI Stock Payouts (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy

Pacira BioSciences (PCRX) Stock Forecast, Price & News

$31.04
-2.16 (-6.51%)
(As of 09/27/2023 ET)
Compare
Today's Range
$30.97
$33.20
50-Day Range
$31.04
$39.48
52-Week Range
$30.97
$58.10
Volume
1.02 million shs
Average Volume
404,898 shs
Market Capitalization
$1.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.00

Pacira BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
86.9% Upside
$58.00 Price Target
Short Interest
Bearish
7.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.97
Upright™ Environmental Score
News Sentiment
1.01mentions of Pacira BioSciences in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$42,773 Sold Last Quarter
Proj. Earnings Growth
39.66%
From $2.37 to $3.31 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.87 out of 5 stars

Medical Sector

56th out of 976 stocks

Pharmaceutical Preparations Industry

12th out of 450 stocks


PCRX stock logo

About Pacira BioSciences (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

PCRX Price History

PCRX Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Pacira BioSciences Chairman, CEO David Stack to Retire
Pacira BioSciences Announces Leadership Succession Plan
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
4 Analysts Have This to Say About Pacira BioSciences
Analyst Ratings for Pacira BioSciences
PCRX - Pacira BioSciences, Inc.
Pacira BioSciences (NASDAQ: PCRX)
Barclays Releases a Buy Rating on Pacira Pharmaceuticals (PCRX)
See More Headlines
Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PCRX Company Calendar

Last Earnings
8/02/2023
Today
9/28/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:PCRX
CUSIP
69512710
Employees
715
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$58.00
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+86.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$15.91 million
Pretax Margin
-0.69%

Debt

Sales & Book Value

Annual Sales
$666.82 million
Cash Flow
$3.80 per share
Book Value
$16.89 per share

Miscellaneous

Free Float
43,353,000
Market Cap
$1.44 billion
Optionable
Optionable
Beta
0.70
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. David M. StackMr. David M. Stack (Age 73)
    Chairman & CEO
    Comp: $1.54M
  • Mr. Charles A. Reinhart IIIMr. Charles A. Reinhart III (Age 62)
    CPA, M.B.A., Chief Financial Officer
    Comp: $780.58k
  • Mr. Daryl Gaugler (Age 61)
    Chief Operating Officer
    Comp: $778.77k
  • Ms. Kristen Williams J.D. (Age 49)
    Chief Admin. Officer & Sec.
    Comp: $799.63k
  • Mr. Anthony Molloy III (Age 49)
    Esq., Chief Legal & Compliance Officer
    Comp: $581.41k
  • Ms. Lauren Bullaro Riker (Age 44)
    Principal Accounting Officer & VP of Fin.
  • Susan Mesco
    Head of Investor Relations
  • Mr. Richard Kahr
    VP of HR
  • Dr. Roy Winston M.D. (Age 62)
    Chief Medical Officer & Orthopedic Franchise
  • Mr. Dennis McLoughlin (Age 57)
    Chief Customer Officer













PCRX Stock - Frequently Asked Questions

Should I buy or sell Pacira BioSciences stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PCRX shares.
View PCRX analyst ratings
or view top-rated stocks.

What is Pacira BioSciences' stock price forecast for 2023?

9 brokerages have issued 12 month target prices for Pacira BioSciences' shares. Their PCRX share price forecasts range from $50.00 to $80.00. On average, they predict the company's stock price to reach $58.00 in the next year. This suggests a possible upside of 86.9% from the stock's current price.
View analysts price targets for PCRX
or view top-rated stocks among Wall Street analysts.

How have PCRX shares performed in 2023?

Pacira BioSciences' stock was trading at $38.61 at the beginning of 2023. Since then, PCRX stock has decreased by 19.6% and is now trading at $31.04.
View the best growth stocks for 2023 here
.

When is Pacira BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PCRX earnings forecast
.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) announced its quarterly earnings data on Wednesday, August, 2nd. The company reported $0.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.59 by $0.02. The business earned $169.47 million during the quarter, compared to analyst estimates of $175.64 million. Pacira BioSciences had a positive trailing twelve-month return on equity of 11.56% and a negative net margin of 0.68%.

What ETFs hold Pacira BioSciences' stock?
What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

What is Pacira BioSciences' stock symbol?

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by many different retail and institutional investors. Top institutional investors include Frontier Capital Management Co. LLC (3.63%), Baillie Gifford & Co. (3.61%), Renaissance Technologies LLC (3.39%), Stephens Investment Management Group LLC (2.88%), Clearbridge Investments LLC (2.49%) and Dimensional Fund Advisors LP (2.42%). Insiders that own company stock include Andreas Wicki, Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends
.

How do I buy shares of Pacira BioSciences?

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacira BioSciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $31.04.

How much money does Pacira BioSciences make?

Pacira BioSciences (NASDAQ:PCRX) has a market capitalization of $1.44 billion and generates $666.82 million in revenue each year. The company earns $15.91 million in net income (profit) each year or ($0.16) on an earnings per share basis.

How many employees does Pacira BioSciences have?

The company employs 715 workers across the globe.

How can I contact Pacira BioSciences?

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The official website for the company is www.pacira.com. The company can be reached via phone at (813) 553-6680, via email at susan.mesco@pacira.com, or via fax at 302-655-5049.

This page (NASDAQ:PCRX) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -